Proteomic Profiling Services for Bladder Cancer
Proteomic analysis plays a crucial role in understanding the complex molecular landscape of bladder cancer. Alfa Cytology provides proteomic profiling services for bladder cancer research and assists our customers in achieving their goals.
Introduction to Proteomic in Bladder Cancer
Regulation of protein expression and pathway activity cannot be inferred from genomic or transcriptomic data, but is key to understanding how new drugs affect their targets and broader disease biology. Proteomics is now widely used in bladder cancer research, such as pathogenesis studies, biomarker discovery, drug discovery and development, toxicological testing, and more.
Fig.1 Development of proteomic tools for the early detection of bladder cancer. (Ahn J. H., et al. 2022)
Proteomics involves the large-scale analysis of proteins in a biological sample, providing insights into their expression levels, post-translational modifications, protein-protein interactions, and cellular localization. By studying the global protein profile of bladder cancer cells or tissues, proteomic techniques help identify dysregulated proteins and signaling pathways associated with bladder cancer initiation, progression, and metastasis. This knowledge can significantly contribute to the development of targeted therapies and personalized medicine approaches.
Our Services
Alfa Cytology, a leading preclinical CRO company, offers comprehensive proteomic services specifically tailored to bladder cancer research. Relying on our high-throughput mass spectrometry platform and practical experience, we provide a series of services such as protein mass spectrometry identification, protein quantitative genomics, protein post-translational modification genomics and bioinformatics.
| Our Services |
Specification |
Samples |
Technology |
| Discovery Proteomics |
- Development of surrogate endpoints
- Target identification and validation
- Pharmacodynamic efficacy
- Drug target specificity and identification
- Toxicology profiling
- Translational research
|
Cell: >107
Serum: >100 μL
Tissue: >100 mg
Urine: >10 mL
Xenografts |
LC-MS/MS
SDS-PAGE
RP-HPLC
ES-MS/MS
Immobilised Metal Affinity Chromatography (IMAC) |
| Targeted Proteomics |
- DMPK analysis
- Biomarker validation in large cohorts
- Detection of low levels of peptides present in the mixture
|
| Post Translational Modifications (PTM) Analysis |
- Identification and quantification of thousands of PTM sites in samples
- Disease mechanisms
- Elucidation of signal transduction
- Signalling pathway modulation
|
| Proteomics Analysis of Exosomes |
- Phosphorylated exosomal proteomic detection service
- Four-Dimensional exosomal proteomic detection service
- Label-free exosomal proteomic detection service
- Labeled exosomal proteomic detection service
- MRM/PRM Targeted exosomal proteomic detection service
- Glycosylated exosome detection services
- Ultra-sensitive Targeted exosomal proteomic detection service
|
| Protein-Protein Interaction Analysis |
- Identifying key protein interactions in bladder cancer to develop targeted drug therapies.
- Examining drug candidates' interactions with target proteins to enhance drug development.
- Functional analysis: Understanding the biological mechanisms of bladder cancer by elucidating the function of proteins in complex networks.
|
Our Advantages
- Enhanced Expertise
- Advanced Methodologies
- Practical Outcomes
- Cutting-Edge Technology
- Customized Approaches
- Stringent Quality Control
Contact Us
Our specialized proteomics workflow can be applied to all aspects of bladder cancer drug development to provide deeper insights, discover candidate biomarkers and make better decisions. Contact us today to discuss your project requirements and learn how our proteomics services can accelerate your research and contribute to advancements in bladder cancer diagnosis and therapy.
References
- Ahn J. H., Kang C. K., and et al. Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers. Life. 2022, 12(3): 395.
For research use only. Not intended for any clinical use.
Related Services
